hVIVO PLC GBP6.3m HRV contract signed with biotech client (2639Y)

TIDMHVO

RNS Number : 2639Y

hVIVO PLC

02 January 2024

hVIVO plc

("hVIVO" or the "Company")

GBP6.3m HRV contract signed with biotechnology client

Highlights

   --    Study to enter hVIVO's state-of-the-art Canary Wharf quarantine facilities in H2 2024 
   --    Potential to enhance value of the client's antiviral by generating efficacy data in HRV

hVIVO plc (AIM & Euronext: HVO) , the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a GBP6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV - common cold virus) Human Challenge Study Model.

The Phase 2a randomised, double-blinded placebo-controlled human challenge trial is planned to take place at the Company's new specialist state-of-the-art quarantine facilities in Canary Wharf. It will evaluate the effect of the antiviral candidate on viral load, safety, tolerability, and prophylactic antiviral activity against HRV infection in multiple cohorts of healthy volunteers.

The study is expected to commence in H2 2024, with revenue recognised in 2024 and 2025. As part of the study, hVIVO will recruit healthy volunteers via the Company's dedicated volunteer recruitment arm, FluCamp. This biotechnology client recognises the benefit of human challenge in quickly generating early human efficacy data, which has the potential of significantly enhancing the value of their clinical asset.

Human rhinoviruses (HRV) are a group of pathogens that cause 'the common cold', with over 150 distinct types of HRV currently known. Although one third of HRV infections are asymptomatic, it can be potentially serious in the elderly, immunocompromised and those with existing respiratory diseases, and there is strong evidence of a relationship between HRV infection and more severe symptoms of asthma and COPD.(1) To date, no antiviral has been approved in the prevention or treatment of HRV infection.

Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "We are delighted to be partnering with this biotech client to investigate the use of their antiviral candidate against HRV. Our human challenge trials can provide quick efficacy data, that has the potential to significantly enhance the value of our clients' assets, something which is critical in the current tight biotech investment landscape. There is renewed focus and capital available to biopharma companies with assets targeting respiratory disease indications. Our HRV Human Challenge Model offers our clients the opportunity to open up these markets, given HRV's association to exacerbation of asthma and COPD."

Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said: "With our new state-of-the-art facility, we are able to conduct significantly more multi-cohort challenge trials concurrently, providing quick efficacy data to accelerate drug development. There remains no approved antiviral to treat HRV infections, despite their dangerous impact on large and vulnerable population groups. I look forward to following the progress of this antiviral candidate when it enters the clinic later this year."

(1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787546/#

For further information please contact:

 
 hVIVO plc                                                           +44 (0) 20 7756 1300 
 Yamin 'Mo' Khan, Chief Executive 
  Officer 
  Stephen Pinkerton, Chief Financial 
  Officer 
 
 Liberum Capital (Nominated Adviser and 
  Joint Broker)                                                      +44 (0) 20 3100 2000 
 Ben Cryer, Edward Mansfield, Phil Walker, 
  Will King 
 
 Cavendish Capital Markets Limited (Joint 
  Broker)                                                            +44 (0) 20 7220 0500 
 Geoff Nash, Charlie Beeson, Nigel Birks, 
  Harriet Ward 
 
 Davy (Euronext Growth Adviser and Joint 
  Broker)                                                             +353 (0) 1 679 6363 
 Anthony Farrell, Niall Gilchrist 
 
 Walbrook PR (Financial PR & IR)             +44 (0) 20 7933 8780 or hvivo@walbrookpr.com 
  Stephanie Cuthbert / Phillip                    +44 (0) 7796 794 663 / +44 (0) 7867 984 
  Marriage /                                                                        082 / 
  Louis Ashe-Jepson                                                  +44 (0) 7747 515 393

Notes to Editors

About hVIVO

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTFLFEDFSLAFIV

(END) Dow Jones Newswires

January 02, 2024 02:00 ET (07:00 GMT)

hVIVO (AQSE:HVO.GB)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024